comparemela.com

Latest Breaking News On - Astellas gene therapies center - Page 1 : comparemela.com

Astellas Celebrates the Opening of Its New Large-Scale Gene Therapy Manufacturing Facility in North Carolina

Press release content from PR Newswire. The AP news staff was not involved in its creation.

Enterprise parkUnited statesNorth carolinaLee countySouth san franciscoSan franciscoMathew pletcherKenji yasukawaRoy cooperAstellas pharma incAstellas gene therapies centerPrnewswire astellas pharma incAstellas centerDivision head of gene therapy researchAudentes therapeutics incSenior vice president

Astellas Celebrates the Opening of Its New Large-Scale Gene Therapy Manufacturing Facility in North Carolina

/PRNewswire/ Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced the opening of a new late-stage clinical.

Enterprise parkUnited statesLee countyNorth carolinaSouth san franciscoSan franciscoRoy cooperAstellas pharma incAstellas gene therapies centerAstellas centerAudentes therapeutics incPark driveAstellas gene therapiesGovernor royFocus area approachGene therapies

Astellas Gene Therapy Plant Opens in Sanford | North Carolina Biotechnology Center

.Following two years of development, Astellas’ new late-stage clinical and commercial manufacturing plant officially opened its doors in Sanford today, June 8.

Lee countyNorth carolinaUnited statesCity of sanfordUniversity of north carolinaMathew pletcherJude samulskiRichard jude samulskiRoy cooperResearch triangle asklepios biopharmaceuticalCarolina biotechnology centerJob development investment grantDrug administrationGene therapy researchSanford area growth allianceCarolina department of commerce

Astellas Announces Positive Safety Data from the FORTIS Study of AT845 in Adults with Late-Onset Pompe Disease

TOKYO, Feb. 7, 2022 /PRNewswire/ Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., Astellas ) today announced positiv.

United statesSan franciscoNorth carolinaSouth san franciscoKenji yasukawaTahseen mozaffarWeston millerIsrael journal of medical sciencesClinical development at astellasPediatric researchAstellas pharma incAstellas gene therapies centerAstellas centerPrnewswire astellas pharma incAudentes therapeutics incAmerican college of medical genetics

Astellas Announces Positive Safety Data from the FORTIS Study of AT845 in Adults with Late-Onset Pompe Disease

/PRNewswire/ Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced positive interim safety data from.

United statesSan franciscoNorth carolinaSouth san franciscoKenji yasukawaTahseen mozaffarWeston millerIsrael journal of medical sciencesClinical development at astellasPediatric researchAstellas pharma incAstellas gene therapies centerAstellas centerPrnewswire astellas pharma incAudentes therapeutics incAmerican college of medical genetics

vimarsana © 2020. All Rights Reserved.